857664-99-4

Basic information

• Product Name: methyl 5-(benzoyloxy)-2-(2-(benzyloxycarbonylamino)propan-2-yl)-6-methoxypyrimidine-4-carboxylate
• Synonyms: methyl 5-(benzoyloxy)-2-(2-(benzyloxycarbonylamino)propan-2-yl)-6-methoxypyrimidine-4-carboxylate
• CAS NO: 857664-99-4
• Molecular Weight: 479.489
• Mol File: 857664-99-4.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: methyl 5-(benzoyloxy)-2-(2-(benzyloxycarbonylamino)propan-2-yl)-6-methoxypyrimidine-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 5-(benzoyloxy)-2-(2-(benzyloxycarbonylamino)propan-2-yl)-6-methoxypyrimidine-4-carboxylate(857664-99-4)
• EPA Substance Registry System: methyl 5-(benzoyloxy)-2-(2-(benzyloxycarbonylamino)propan-2-yl)-6-methoxypyrimidine-4-carboxylate(857664-99-4)

Safety Data

• Hazardous Substances Data: 857664-99-4(Hazardous Substances Data)

Upstream product

• 501-53-1 benzyl chloroformate 
• 81587-18-0 benzyl N-(2-amino-1,1-dimethyl-2-oxo-ethyl)carbamate 
• 100134-82-5 (cyano-dimethyl-methyl)carbamic acid benzyl ester 
• 15030-72-5 Z-Aib-OH 
• 518048-00-5 methyl 5-(benzoyloxy)-2-(2-(benzyloxycarbonylamino)propan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxylate 
• 77-78-1 dimethyl sulfate 
• 518047-98-8 [1-(N'-hydroxycarbamimidoyl)-1-methyl-ethyl]carbamic acid benzyl ester 
• 518048-00-5 methyl 5-(benzoyloxy)-2-(1-{[(benzyloxy)carbonyl]amino}-1-methylethyl)-6-hydroxypyrimidine-4-carboxylate 

Downstream Products

• 1370588-46-7 2-[5-(benzoyloxy)-4-(methoxycarbonyl)-6-methoxypyrimidin-2-yl]propan-2-amine hydrochloride 
• 1370588-47-8 methyl 5-(benzoyloxy)-6-methoxy-2-(2-(5-methyl-1,3,4-oxadiazole-2-carboxamido)propan-2-yl)pyrimidine-4-carboxylate 
• 1370588-48-9 N-(2-(4-(4-fluorobenzylcarbamoyl)-5-hydroxy-6-methoxypyrimidin-2-yl)propan-2-yl)-5-methyl-1,3,4-oxadiazole-2-carboxamide 
• 1370588-49-0 potassium 4-(4-fluorobenzylcarbamoyl)-6-methoxy-2-(2-(5-methyl-1,3,4-oxadiazole-2-carboxamido)propan-2-yl)pyrimidin-5-olate 
• 1370588-50-3 N-(2-(4-(4-fluorobenzylamino)-6-(4-fluorobenzylcarbamoyl)-5-hydroxypyrimidin-2-yl)propan-2-yl)-5-methyl-1,3,4-oxadiazole-2-carboxamide 
• 1370588-65-0 N₁,N₁-diethyl-N₂-(2-(4-(4-fluorobenzylcarbamoyl)-5-hydroxy-6-methoxypyrimidin-2-yl)propan-2-yl)oxalamide 
• 1370588-54-7 4-(4-fluorobenzylcarbamoyl)-6-methoxy-2-(2-(5-methyl-1,3,4-oxadiazole-2-carboxamido)propan-2-yl)pyrimidin-5-yl acetate 
• 1370588-55-8 4-(4-fluorobenzylcarbamoyl)-6-methoxy-2-(2-(5-methyl-1,3,4-oxadiazole-2-carboxamido)propan-2-yl)pyrimidin-5-yl methanesulfonate 
• 1370588-56-9 4-(4-fluorobenzylcarbamoyl)-6-methoxy-2-(2-(5-methyl-1,3,4-oxadiazole-2-carboxamido)propan-2-yl)pyrimidin-5-yl benzoate 
• 1370588-57-0 4-(4-fluorobenzylcarbamoyl)-6-methoxy-2-(2-(5-methyl-1,3,4-oxadiazole-2-carboxamido)propan-2-yl)pyrimidin-5-yl 2,4,6-trimethylbenzenesulfonate 
• 1370588-66-1 2-(2-(2-(diethylamino)-2-oxoacetamido)propan-2-yl)-4-(4-fluorobenzylcarbamoyl)-6-methoxypyrimidin-5-yl acetate 
• 1370588-67-2 2-(2-(2-(diethylamino)-2-oxoacetamido)propan-2-yl)-4-(4-fluorobenzylcarbamoyl)-6-methoxypyrimidin-5-yl methanesulfonate 
• 1370588-68-3 2-(2-(2-(diethylamino)-2-oxoacetamido)propan-2-yl)-4-(4-fluorobenzylcarbamoyl)-6-methoxypyrimidin-5-yl benzoate 
• 1370588-69-4 2-(2-(2-(diethylamino)-2-oxoacetamido)propan-2-yl)-4-(4-fluorobenzylcarbamoyl)-6-methoxypyrimidin-5-yl 2,4,6-trimethylbenzenesulfonate 

Relevant articles and documents

Hydroxyl may not be indispensable for raltegravir: Design, synthesis and SAR Studies of raltegravir derivatives as HIV-1 inhibitors

A series of raltegravir derivatives 20-42 were prepared and systematically evaluated for their anti-HIV activity. The bioassay results showed that most of the compounds possess good to excellent anti-HIV activity. Especially, compounds 25 and 35 with subpicomole IC50 values seemed to be the most potent anti-HIV agents among all of the reported synthesized compounds. These compounds may therefore be considered as new potent anti-HIV agents. The 5-hydroxyl modification of raltegravir derivatives significantly increased the anti-HIV activity, which indicates that the hydroxyl may not be indispensable for raltegravir. The introducing of acyl at 5-position of raltegravir derivatives is favorable for antiviral activity. In addition, a high-throughput cell-based assay method with pseudotyped virus stocks was developed and used to identify HIV inhibitors.